Alzamend Neuro, Inc.(ALZN)Earnings, Financials & Key Ratios
ALZN•NASDAQ
$1.20
Price updated Jun 27, 2026
AboutAlzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.Show more
- Revenue$0
- EBITDA-$4M+55.0%
- Net Income-$5M+54.6%
- EPS (Diluted)-11.32+91.4%
- ROE-657.17%+85.1%
ALZN Price & Volume
Alzamend Neuro, Inc. (ALZN) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Threatens Future Capital Solvency
Investment Thesis • Updated 2026Q3
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
Key Thesis Takeaways
- Alzamend Neuro remains a high-risk, pre-commercial biotechnology entity entirely dependent on dilutive equity financing to sustain its R&D-heavy clinical pipeline.
- The company's inability to generate meaningful revenue, evidenced by the absence of top-line growth since 2024Q4, leaves its long-term viability tethered to successful clinical trial outcomes.
- Investors should monitor the rapid erosion of cash reserves, which fell from $5.6 million in 2026Q1 to $2.7 million by 2026Q3, as this trajectory necessitates further capital raises that may significantly dilute existing shareholders.
Verdict Logic
the company's precarious liquidity position, evidenced by a cash balance that contracted by over 50% between 2026Q1 and 2026Q3, suggests an imminent risk of further dilutive financing to support ongoing operations.
ALZN Growth Metrics
Alzamend Neuro, Inc. (ALZN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-66.61%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM83.53%
Return on Capital
10 Years-8783.89%
5 Years-1149.93%
3 Years-1746.64%
Last Year-654.54%
Peers Comparison
Key metrics vs top competitors for Alzamend Neuro, Inc. (ALZN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.20 | $4.57M | -0.11 | — | — | -657.17% | — | |
| $1.32 | $63.77M | -2.54 | — | — | -95.77% | — | |
| $1.72 | $33.84M | -1.23 | — | — | -318.08% | — | |
| $327.79 | $9.47B | -24.32 | -100% | — | -43.02% | — | |
| $2.56 | $260.54M | -2.96 | -86.92% | -1971.7% | -101.76% | — | |
| $216.03 | $31.89B | 24.47 | 1.39% | 13.92% | 7.55% | — |
Compare ALZN vs Peers
Alzamend Neuro, Inc. (ALZN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when ALZN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ALZN Frequently Asked Questions
Alzamend Neuro, Inc. (ALZN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is ALZN profitable?
Alzamend Neuro, Inc. (ALZN) reported a net loss of $7.0M for fiscal year 2025.
Dividend & Returns
What is ALZN's return on equity?
Alzamend Neuro, Inc. (ALZN) has a return on equity (ROE) of -657.2%. Negative ROE indicates the company is unprofitable.
What is Alzamend Neuro, Inc.'s free cash flow?
Alzamend Neuro, Inc. (ALZN) had negative free cash flow of $6.2M in fiscal year 2025, likely due to heavy capital investments.